Bi-Specific MAbS Global Market Report 2024

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The expansion observed during the historical period can be ascribed to a surge in healthcare spending, heightened financial support, and proactive government initiatives.

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The anticipated growth in the forecast period is driven by a rising prevalence of cancer, a growing aging population, and an upswing in chronic diseases. Key trends expected in this period encompass a strong emphasis on technological advancements, continuous product innovation, a focus on artificial intelligence integration, investments in targeted and combination therapies, and the establishment of strategic partnerships.

The anticipated rise in cancer and other chronic diseases is poised to significantly bolster the growth of the bispecific monoclonal antibodies (MAbs) market in the foreseeable future. Bispecific monoclonal antibodies are tailored for treating a spectrum of conditions including various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Distinguished by their ability to target multiple tumor antigens, these antibodies are considered more efficacious than conventional monoclonal antibodies (moAbs) in impeding cancer progression. For instance, the American Cancer Society (ACS) projected an estimated 609,820 cancer-related deaths in the USA in 2023, accentuating the increasing need for bi-specific MAbs to effectively combat chronic diseases, notably cancer.

Government initiatives geared towards healthcare research and development are poised to propel the growth of the bispecific MAbs market. These initiatives encompass specific actions, policies, or programs undertaken by governmental bodies to address healthcare challenges, achieve defined objectives, or instigate positive societal changes. An illustrative example involves the collaboration between the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), and Regeneron Pharmaceuticals Inc., a US-based science and technology company. Their collaboration under the U.S. Department of Health and Human Services' 'Project NextGen' aims to develop a next-generation monoclonal antibody therapy for preventing SARS-CoV-2 infection. BARDA's commitment to fund up to 70% of Regeneron's clinical development expenses for this therapy, amounting to an estimated contract value of approximately $326 million, exemplifies governmental support for healthcare research and development. Such initiatives drive advancements and contribute to the growth of the bispecific MAbs market.

Companies within the Bi-Specific MAbS market are increasingly engaging in strategic initiatives, particularly collaborations and partnerships, aimed at expanding their product portfolios and global reach. These collaborations represent cooperative ventures between multiple organizations to achieve shared objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical firm, partnered with MacroGenics, another US-based biopharmaceutical company, in an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3. This initiative, utilizing MacroGenics' DART platform, includes two additional bispecific research programs. Gilead secured an exclusive option to license MGD024, designed to address various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024's unique design aims to mitigate cytokine-release syndrome (CRS) and facilitate intermittent dosing, potentially enhancing treatment convenience and improving clinical outcomes for AML and MDS patients.

Key players in the Bi-Specific MAbS market are leveraging advanced technologies, particularly bispecific monoclonal antibodies, to gain a competitive edge. These artificial proteins have the capability to simultaneously bind to two different types of antigens, targeting specific molecules on cell surfaces. For instance, in September 2021, Amgen, a US-based biopharmaceutical company, collaborated with Boehringer Ingelheim, a Germany-based pharmaceutical company, on a Phase II-ready project. Encouraging clinicians to transition to bispecific mAbs would require substantial improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier disease stage, modifying administration methods, or adjusting treatment frequency, could be viable but necessitate strategic planning from developers. Bispecific mAbs have the potential not only to outperform competitors but also to potentially impact the market share of CAR-T cell therapies, especially in the relapsed or refractory multiple myeloma segment.

In March 2021, Takeda Pharmaceutical Company Limited, a prominent pharmaceutical company based in Japan, successfully acquired Maverick Therapeutics for an undisclosed sum. This strategic acquisition positions Takeda to advance its capabilities in bispecific antibody technology. The synergy between the two entities is expected to enhance resources and leverage accumulated expertise, thereby accelerating the development of Takeda's T-cell engager platform and expanding its pipeline of innovative bispecific immunotherapies. Maverick Therapeutics, a U.S.-based company specializing in biospecific monoclonal antibodies, brings valuable assets and knowledge to further strengthen Takeda's position in the evolving landscape of immunotherapy.

Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc., Johnson & Johnson, Innovent Biologics, Sino Biological Inc., Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc., Eli Lilly Company Inc., AbbVie Inc., Bayer AG, Pfizer Inc., Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa.

North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bi-specific mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Prominent examples of bispecific monoclonal antibodies include catumaxomab (utilized for malignant ascites treatment), blinatumomab, duligotumab, and SAR 156597. Catumaxomab, a rat-mouse hybrid monoclonal antibody, addresses malignant ascites linked to metastasizing cancer. These innovative antibodies find application in both in vivo and in vitro settings, contributing to the treatment of conditions such as cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and microbial diseases. Hospitals, research institutes, and other healthcare entities leverage bispecific monoclonal antibodies to enhance therapeutic interventions and advance medical research.

The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.